Sarepta Therapeutics Inc. (NASDAQ:SRPT) CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,217,600.00. Following the completion of the sale, the chief executive officer now owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded up 0.88% during midday trading on Wednesday, reaching $56.22. The company’s stock had a trading volume of 8,767,424 shares. The firm has a 50 day moving average price of $29.05 and a 200-day moving average price of $21.62. Sarepta Therapeutics Inc. has a 12-month low of $8.00 and a 12-month high of $58.87. The company’s market cap is $2.69 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the previous year, the business posted ($0.87) earnings per share. On average, equities research analysts predict that Sarepta Therapeutics Inc. will post ($4.17) earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its position in Sarepta Therapeutics by 2.3% in the first quarter. Creative Planning now owns 54,150 shares of the company’s stock worth $1,057,000 after buying an additional 1,200 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. Franklin Resources Inc. acquired a new position in Sarepta Therapeutics during the first quarter worth approximately $13,506,000. BlackRock Fund Advisors boosted its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares in the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.

SRPT has been the subject of a number of recent research reports. Wedbush restated a “neutral” rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, May 25th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Robert W. Baird reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $51.01.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.